Clipos™ Tanespimycin (17-AAG) Encapsulated Liposomes
Specifications
Description
|
PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only. |
Lipid composition
|
PEGylated Liposomes |
Liposome Size
|
70-120 nm |
Lipid Molar Concentration
|
60 mM |
Encapsulated Drug
|
Tanespimycin |
Drug concentration
|
2.5 mg/mL |
Inside Buffer
|
300 mM sucrose |
Outside Buffer
|
300 mM sucrose |
Storage
|
2 °C to 8 °C (do not freeze), protect from light |
Shelf-life
|
At least 1 month |
Related Products